Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics Statistics

Total Valuation

CTNM has a market cap or net worth of $403.29 million. The enterprise value is $223.45 million.

Market Cap	403.29M
Enterprise Value	223.45M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026, after market close.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

CTNM has 36.53 million shares outstanding. The number of shares has increased by 96.27% in one year.

Current Share Class	30.45M
Shares Outstanding	36.53M
Shares Change (YoY)	+96.27%
Shares Change (QoQ)	+8.57%
Owned by Insiders (%)	0.89%
Owned by Institutions (%)	37.32%
Float	26.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.90
P/TBV Ratio	2.22
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 29.07, with a Debt / Equity ratio of 0.03.

Current Ratio	29.07
Quick Ratio	28.68
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -30.40% and return on invested capital (ROIC) is -21.42%.

Return on Equity (ROE)	-30.40%
Return on Assets (ROA)	-20.89%
Return on Invested Capital (ROIC)	-21.42%
Return on Capital Employed (ROCE)	-36.85%
Revenue Per Employee	n/a
Profits Per Employee	-$1.45M
Employee Count	41
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.17% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-14.17%
50-Day Moving Average	11.19
200-Day Moving Average	8.09
Relative Strength Index (RSI)	50.17
Average Volume (20 Days)	241,197

Short Selling Information

The latest short interest is 2.45 million, so 6.72% of the outstanding shares have been sold short.

Short Interest	2.45M
Short Previous Month	1.70M
Short % of Shares Out	6.72%
Short % of Float	9.43%
Short Ratio (days to cover)	9.73

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-67.99M
Pretax Income	-59.39M
Net Income	-59.39M
EBITDA	-67.68M
EBIT	-67.99M
Earnings Per Share (EPS)	-$2.25

Balance Sheet

The company has $182.41 million in cash and $5.49 million in debt, with a net cash position of $176.91 million or $4.84 per share.

Cash & Cash Equivalents	182.41M
Total Debt	5.49M
Net Cash	176.91M
Net Cash Per Share	$4.84
Equity (Book Value)	180.47M
Book Value Per Share	6.18
Working Capital	178.57M

Cash Flow

In the last 12 months, operating cash flow was -$52.47 million and capital expenditures -$355,000, giving a free cash flow of -$52.83 million.

Operating Cash Flow	-52.47M
Capital Expenditures	-355,000
Free Cash Flow	-52.83M
FCF Per Share	-$1.45

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CTNM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-96.27%
Shareholder Yield	-96.27%
Earnings Yield	-14.83%
FCF Yield	-13.19%

Analyst Forecast

The average price target for CTNM is $18.60, which is 68.48% higher than the current price. The consensus rating is "Buy".

Price Target	$18.60
Price Target Difference	68.48%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	4.76%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1